{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:03:43Z","timestamp":1791324223922,"version":"4.3.1"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,1]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Thrombotic risk is associated with the estrogen dose and type of progestin in combined oral contraceptives. Studies published since 1990 showed that third-generation progestins have larger risk to contribute to thrombosis development than the second-generation. However, there are conflicts in the literature regarding the thrombotic risk associated to the drospirenone progestin. So, this study aimed to evaluate the effects of 3 formulations of contraceptives containing ethinylestradiol (EE) (20 and 30\u200a\u03bcg) combined with drospirenone versus levonorgestrel combined with EE (30\u200a\u03bcg) in hemostatic parameters.<\/jats:p>\n                    <jats:p>\n                      This cross-sectional study included 70 healthy women between 18 and 30 years, BMI 19 to 30\u200akg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , not pregnant, non-smokers, and users or non-users (control) of contraceptives for a minimum period of 6 months. The following parameters were assessed: prothrombin time (PT), Factor VII, activated partial thromboplastin time (aPTT), Factor XII, fibrinogen, Factor 1\u200a+\u200a2, Protein C, Protein S, antithrombin, D-dimers, and plasminogen activator inhibitor-1.\n                    <\/jats:p>\n                    <jats:p>Significant alterations were found in PT, aPTT, fibrinogen, D-dimers, and protein S, all favoring a state of hypercoagulation for contraceptive containing DRSP\/20EE. Both contraceptives containing DRSP\/30EE and LNG\/30EE promoted changes that favor the hypercoagulability in the coagulant variable PT and in the anticoagulant variables Protein S and Protein C, respectively.<\/jats:p>\n                    <jats:p>We suggest that the progestin drospirenone can contribute to an inadequate balance among procoagulant, anticoagulant, and fibrinolytic factors, since that the contraceptive containing the lowest dose of estrogen and drospirenone (DRSP\/20EE) caused a higher number of hemostatic changes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000000385","type":"journal-article","created":{"date-parts":[[2015,1,29]],"date-time":"2015-01-29T02:05:49Z","timestamp":1422497149000},"page":"e385","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":27,"title":["Comparative Study of the Effects of Combined Oral Contraceptives in Hemostatic Variables"],"prefix":"10.1097","volume":"94","author":[{"given":"Bianca","family":"Stocco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen F.","family":"Fumagalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio A.","family":"Franceschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edson Z.","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cleni M.","family":"Marzocchi-Machado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos Felipe S.","family":"de S\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Regina T.","family":"Toloi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20260903","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2010.01.057","article-title":"Risk factors for venous thromboembolism","volume":"56","author":"Goldhaber","year":"2010","journal-title":"JACC"},{"key":"R2-6-20260903","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2307\/2135857","article-title":"Emergency contraceptive pills: a simple proposal to reduce unintended pregnancies","volume":"24","author":"Trussell","year":"1992","journal-title":"Fam Plann Perspect"},{"key":"R3-6-20260903","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/humupd\/5.6.672","article-title":"Biological coagulation findings in third-generation oral contraceptives","volume":"5","author":"Conard","year":"1999","journal-title":"Hum Reprod Update"},{"key":"R4-6-20260903","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/asheducation.V2005.1.1.1","article-title":"Venous thrombosis: the role of genes, environment, and behavior","volume":"1","author":"Rosendaal","year":"2005","journal-title":"Hematology"},{"key":"R5-6-20260903","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(95)91926-0","article-title":"Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception","volume":"346","author":"Poulter","year":"1995","journal-title":"Lancet"},{"key":"R6-6-20260903","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1136\/bmj.312.7023.83","article-title":"Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study","volume":"312","author":"Spitzer","year":"1996","journal-title":"BMJ"},{"key":"R7-6-20260903","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/archinte.159.1.65","article-title":"Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias","volume":"159","author":"Bloemenkamp","year":"1999","journal-title":"Arch Intern Med"},{"key":"R8-6-20260903","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1046\/j.1365-2125.2000.00198.x","article-title":"A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives","volume":"49","author":"Farmer","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"R9-6-20260903","doi-asserted-by":"crossref","first-page":"b2890","DOI":"10.1136\/bmj.b2890","article-title":"Hormonal contraception and risk of venous thromboembolism: national follow-up study","volume":"339","author":"Lidegaard","year":"2009","journal-title":"BMJ"},{"key":"R10-6-20260903","doi-asserted-by":"crossref","first-page":"b2921","DOI":"10.1136\/bmj.b2921","article-title":"The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study","volume":"339","author":"Van Hylckama","year":"2009","journal-title":"BMJ"},{"key":"R11-6-20260903","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2007.02450.x","article-title":"Incidence and mortality of venous thrombosis: a population-based study","volume":"5","author":"Naess","year":"2007","journal-title":"J Thromb Haemost"},{"key":"R12-6-20260903","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/oxfordjournals.aje.a115799","article-title":"Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease","volume":"133","author":"Gerstman","year":"1991","journal-title":"Am J Epidemiol"},{"key":"R13-6-20260903","first-page":"482","article-title":"Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills?","volume":"81","author":"Odlin","year":"2002","journal-title":"Acta Obstet Gyn Scan"},{"key":"R14-6-20260903","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0140-6736(96)07496-X","article-title":"Population-based study of risk of venous thromboembolism associated with various oral contraceptives","volume":"349","author":"Farmer","year":"1997","journal-title":"Lancet"},{"key":"R15-6-20260903","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/bmj.323.7305.131","article-title":"Third generation oral contraceptives and risk of venous thrombosis: meta-analysis","volume":"323","author":"Kemmeren","year":"2001","journal-title":"Br Med J"},{"key":"R16-6-20260903","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1056\/NEJMcp030751","article-title":"Clinical practice. Combination estrogen-progestin oral contraceptives","volume":"349","author":"Petitti","year":"2003","journal-title":"N Engl J Med"},{"key":"R17-6-20260903","doi-asserted-by":"crossref","first-page":"d2151","DOI":"10.1136\/bmj.d2151","article-title":"Risk of non-fatal venous thrombo - embolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case\u2013control study using United States claims data","volume":"342","author":"Jick","year":"2011","journal-title":"BMJ"},{"key":"R18-6-20260903","doi-asserted-by":"crossref","first-page":"d2139","DOI":"10.1136\/bmj.d2139","article-title":"Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case\u2013control study based on UK General Practice Research Database","volume":"342","author":"Parkin","year":"2011","journal-title":"BMJ"},{"key":"R19-6-20260903","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.contraception.2006.12.019","article-title":"The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142 475 women-years of observation","volume":"75","author":"Dinger","year":"2007","journal-title":"Contraception"},{"key":"R20-6-20260903","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/01.AOG.0000279448.62221.a8","article-title":"Risk of thromboembolism in women taking ethinylestradiol\/drospirenone and other oral contraceptives","volume":"110","author":"Seeger","year":"2007","journal-title":"Obstet Gynecol"},{"key":"R21-6-20260903","first-page":"CD004861","article-title":"Types of progestogens in combined oral contraception: effectiveness and side-effects","volume":"5","author":"Lawrie","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"R22-6-20260903","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.contraception.2012.03.013","article-title":"Drospirenone and levonorgestrel in combination with either 30 or 20 mcg ethinylestradiol reduce soluble adhesion molecules in Brazilian women; cross-sectional study","volume":"86","author":"Stocco","year":"2012","journal-title":"Contraception"},{"key":"R23-6-20260903","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.contraception.2005.09.015","article-title":"A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20\u200a(g ethinylestradiol and a reference containing desogestrel and 30\u200a(g ethinylestradiol","volume":"73","author":"Kluft","year":"2006","journal-title":"Contraception"},{"key":"R24-6-20260903","first-page":"267","article-title":"The quality of diagnostic samples","volume":"26","author":"Guder","year":"2002","journal-title":"J Lab Med"},{"key":"R25-6-20260903","first-page":"1","article-title":"Renewed interest in haemostasis changes induced by oral contraceptives (OCs)","volume":"84","author":"Kluft","year":"2000","journal-title":"Thromb Haemostasis"},{"key":"R26-6-20260903","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.contraception.2004.12.005","article-title":"Effects of two combined oral contraceptives containing ethinyl estradiol 20\u200a(g combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism","volume":"71","author":"Klipping","year":"2005","journal-title":"Contraception"},{"key":"R27-6-20260903","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.thromres.2010.01.045","article-title":"Mechanisms of estrogen-induced venous thromboembolism","volume":"126","author":"Tchaikovski","year":"2010","journal-title":"Thromb Res"},{"key":"R28-6-20260903","first-page":"199","article-title":"Effects of estrogen or estrogenprogestin regimens on heart disease risk factors in postmenopausal women: the postmenopausal estrogenprogestin intervations (PEPI) trial.","volume":"203","year":"1995","journal-title":"JAMA"},{"key":"R29-6-20260903","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1093\/humupd\/dmt028","article-title":"Venous thromboembolism in women: a specific reproductive health risk","volume":"19","author":"Crosignani","year":"2013","journal-title":"Hum Reprod Update"},{"key":"R30-6-20260903","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0010-7824(01)00307-9","article-title":"Oral contraceptives and venous thromboembolism. A five-year national case-control study","volume":"65","author":"Lidegaard","year":"2002","journal-title":"Contraception"},{"key":"R31-6-20260903","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/blood-2003-04-1285","article-title":"Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor V Leiden mutation: a randomized trial","volume":"103","author":"J.M.","year":"2004","journal-title":"Blood"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00005792-201501040-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T18:00:31Z","timestamp":1788458431000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00005792-201501040-00006"}},"subtitle":["An Observational Preliminary Study"],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000000385","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1]]}}}